Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age
Copyright © 2023 Massachusetts Medical Society..
BACKGROUND: Safe and effective vaccines against coronavirus disease 2019 (Covid-19) are urgently needed in young children.
METHODS: We conducted a phase 1 dose-finding study and are conducting an ongoing phase 2-3 safety, immunogenicity, and efficacy trial of the BNT162b2 vaccine in healthy children 6 months to 11 years of age. We present results for children 6 months to less than 2 years of age and those 2 to 4 years of age through the data-cutoff dates (April 29, 2022, for safety and immunogenicity and June 17, 2022, for efficacy). In the phase 2-3 trial, participants were randomly assigned (in a 2:1 ratio) to receive two 3-μg doses of BNT162b2 or placebo. On the basis of preliminary immunogenicity results, a third 3-μg dose (≥8 weeks after dose 2) was administered starting in January 2022, which coincided with the emergence of the B.1.1.529 (omicron) variant. Immune responses at 1 month after doses 2 and 3 in children 6 months to less than 2 years of age and those 2 to 4 years of age were immunologically bridged to responses after dose 2 in persons 16 to 25 years of age who received 30 μg of BNT162b2 in the pivotal trial.
RESULTS: During the phase 1 dose-finding study, two doses of BNT162b2 were administered 21 days apart to 16 children 6 months to less than 2 years of age (3-μg dose) and 48 children 2 to 4 years of age (3-μg or 10-μg dose). The 3-μg dose level was selected for the phase 2-3 trial; 1178 children 6 months to less than 2 years of age and 1835 children 2 to 4 years of age received BNT162b2, and 598 and 915, respectively, received placebo. Immunobridging success criteria for the geometric mean ratio and seroresponse at 1 month after dose 3 were met in both age groups. BNT162b2 reactogenicity events were mostly mild to moderate, with no grade 4 events. Low, similar incidences of fever were reported after receipt of BNT162b2 (7% among children 6 months to <2 years of age and 5% among those 2 to 4 years of age) and placebo (6 to 7% among children 6 months to <2 years of age and 4 to 5% among those 2 to 4 years of age). The observed overall vaccine efficacy against symptomatic Covid-19 in children 6 months to 4 years of age was 73.2% (95% confidence interval, 43.8 to 87.6) from 7 days after dose 3 (on the basis of 34 cases).
CONCLUSIONS: A three-dose primary series of 3-μg BNT162b2 was safe, immunogenic, and efficacious in children 6 months to 4 years of age. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04816643.).
| Errataetall: |
CommentIn: Pediatr Res. 2023 Nov;94(5):1592. - PMID 37069225 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:388 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 388(2023), 7 vom: 16. Feb., Seite 621-634 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Muñoz, Flor M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 22.02.2023 Date Revised 06.11.2023 published: Print ClinicalTrials.gov: NCT04816643 CommentIn: Pediatr Res. 2023 Nov;94(5):1592. - PMID 37069225 Citation Status MEDLINE |
|---|
| doi: |
10.1056/NEJMoa2211031 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352977256 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352977256 | ||
| 003 | DE-627 | ||
| 005 | 20231226054937.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa2211031 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1176.xml |
| 035 | |a (DE-627)NLM352977256 | ||
| 035 | |a (NLM)36791162 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Muñoz, Flor M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2023 | ||
| 500 | |a Date Revised 06.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT04816643 | ||
| 500 | |a CommentIn: Pediatr Res. 2023 Nov;94(5):1592. - PMID 37069225 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Massachusetts Medical Society. | ||
| 520 | |a BACKGROUND: Safe and effective vaccines against coronavirus disease 2019 (Covid-19) are urgently needed in young children | ||
| 520 | |a METHODS: We conducted a phase 1 dose-finding study and are conducting an ongoing phase 2-3 safety, immunogenicity, and efficacy trial of the BNT162b2 vaccine in healthy children 6 months to 11 years of age. We present results for children 6 months to less than 2 years of age and those 2 to 4 years of age through the data-cutoff dates (April 29, 2022, for safety and immunogenicity and June 17, 2022, for efficacy). In the phase 2-3 trial, participants were randomly assigned (in a 2:1 ratio) to receive two 3-μg doses of BNT162b2 or placebo. On the basis of preliminary immunogenicity results, a third 3-μg dose (≥8 weeks after dose 2) was administered starting in January 2022, which coincided with the emergence of the B.1.1.529 (omicron) variant. Immune responses at 1 month after doses 2 and 3 in children 6 months to less than 2 years of age and those 2 to 4 years of age were immunologically bridged to responses after dose 2 in persons 16 to 25 years of age who received 30 μg of BNT162b2 in the pivotal trial | ||
| 520 | |a RESULTS: During the phase 1 dose-finding study, two doses of BNT162b2 were administered 21 days apart to 16 children 6 months to less than 2 years of age (3-μg dose) and 48 children 2 to 4 years of age (3-μg or 10-μg dose). The 3-μg dose level was selected for the phase 2-3 trial; 1178 children 6 months to less than 2 years of age and 1835 children 2 to 4 years of age received BNT162b2, and 598 and 915, respectively, received placebo. Immunobridging success criteria for the geometric mean ratio and seroresponse at 1 month after dose 3 were met in both age groups. BNT162b2 reactogenicity events were mostly mild to moderate, with no grade 4 events. Low, similar incidences of fever were reported after receipt of BNT162b2 (7% among children 6 months to <2 years of age and 5% among those 2 to 4 years of age) and placebo (6 to 7% among children 6 months to <2 years of age and 4 to 5% among those 2 to 4 years of age). The observed overall vaccine efficacy against symptomatic Covid-19 in children 6 months to 4 years of age was 73.2% (95% confidence interval, 43.8 to 87.6) from 7 days after dose 3 (on the basis of 34 cases) | ||
| 520 | |a CONCLUSIONS: A three-dose primary series of 3-μg BNT162b2 was safe, immunogenic, and efficacious in children 6 months to 4 years of age. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04816643.) | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 700 | 1 | |a Sher, Lawrence D |e verfasserin |4 aut | |
| 700 | 1 | |a Sabharwal, Charu |e verfasserin |4 aut | |
| 700 | 1 | |a Gurtman, Alejandra |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Kitchin, Nicholas |e verfasserin |4 aut | |
| 700 | 1 | |a Lockhart, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Riesenberg, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Sexter, Joanna M |e verfasserin |4 aut | |
| 700 | 1 | |a Czajka, Hanna |e verfasserin |4 aut | |
| 700 | 1 | |a Paulsen, Grant C |e verfasserin |4 aut | |
| 700 | 1 | |a Maldonado, Yvonne |e verfasserin |4 aut | |
| 700 | 1 | |a Walter, Emmanuel B |e verfasserin |4 aut | |
| 700 | 1 | |a Talaat, Kawsar R |e verfasserin |4 aut | |
| 700 | 1 | |a Englund, Janet A |e verfasserin |4 aut | |
| 700 | 1 | |a Sarwar, Uzma N |e verfasserin |4 aut | |
| 700 | 1 | |a Hansen, Caitlin |e verfasserin |4 aut | |
| 700 | 1 | |a Iwamoto, Martha |e verfasserin |4 aut | |
| 700 | 1 | |a Webber, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a Cunliffe, Luke |e verfasserin |4 aut | |
| 700 | 1 | |a Ukkonen, Benita |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez, Silvina N |e verfasserin |4 aut | |
| 700 | 1 | |a Pahud, Barbara A |e verfasserin |4 aut | |
| 700 | 1 | |a Munjal, Iona |e verfasserin |4 aut | |
| 700 | 1 | |a Domachowske, Joseph B |e verfasserin |4 aut | |
| 700 | 1 | |a Swanson, Kena A |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Koury, Kenneth |e verfasserin |4 aut | |
| 700 | 1 | |a Mather, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Xuping |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Pei-Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Cooper, David |e verfasserin |4 aut | |
| 700 | 1 | |a Türeci, Özlem |e verfasserin |4 aut | |
| 700 | 1 | |a Şahin, Uğur |e verfasserin |4 aut | |
| 700 | 1 | |a Jansen, Kathrin U |e verfasserin |4 aut | |
| 700 | 1 | |a Gruber, William C |e verfasserin |4 aut | |
| 700 | 0 | |a C4591007 Clinical Trial Group |e verfasserin |4 aut | |
| 700 | 1 | |a Acevedo, Armando |e investigator |4 oth | |
| 700 | 1 | |a Adkinson, Rachel |e investigator |4 oth | |
| 700 | 1 | |a Anderson, Evan |e investigator |4 oth | |
| 700 | 1 | |a Armiñana, Angels Ulied |e investigator |4 oth | |
| 700 | 1 | |a Arora, Samir |e investigator |4 oth | |
| 700 | 1 | |a Baker, Jeffrey |e investigator |4 oth | |
| 700 | 1 | |a Barnett, Elizabeth |e investigator |4 oth | |
| 700 | 1 | |a Bocchini, Claire |e investigator |4 oth | |
| 700 | 1 | |a Bollyky, Jenna |e investigator |4 oth | |
| 700 | 1 | |a Boppana, Suresh |e investigator |4 oth | |
| 700 | 1 | |a Caserta, Mary |e investigator |4 oth | |
| 700 | 1 | |a Casey, Janet |e investigator |4 oth | |
| 700 | 1 | |a Chalhoub, Fadi |e investigator |4 oth | |
| 700 | 1 | |a Conejo, Pablo Rojo |e investigator |4 oth | |
| 700 | 1 | |a Czajka, Hanna |e investigator |4 oth | |
| 700 | 1 | |a Davis, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Day, J Chris |e investigator |4 oth | |
| 700 | 1 | |a De Valle, Oscar |e investigator |4 oth | |
| 700 | 1 | |a Dever, Michael |e investigator |4 oth | |
| 700 | 1 | |a Domachowske, Joseph |e investigator |4 oth | |
| 700 | 1 | |a Eder, Frank |e investigator |4 oth | |
| 700 | 1 | |a Englund, Janet |e investigator |4 oth | |
| 700 | 1 | |a Feijoo, Brittany |e investigator |4 oth | |
| 700 | 1 | |a Fergie, Jaime |e investigator |4 oth | |
| 700 | 1 | |a Frenck, Robert |c Jr |e investigator |4 oth | |
| 700 | 1 | |a Guasch, Clàudia Fortuny |e investigator |4 oth | |
| 700 | 1 | |a Hand, Jonathan |e investigator |4 oth | |
| 700 | 1 | |a Hartman, Aaron |e investigator |4 oth | |
| 700 | 1 | |a Kantele, Anu |e investigator |4 oth | |
| 700 | 1 | |a Klein, Terry |e investigator |4 oth | |
| 700 | 1 | |a Kokko, Satu |e investigator |4 oth | |
| 700 | 1 | |a Kopinska, Elzbieta |e investigator |4 oth | |
| 700 | 1 | |a Korbal, Piotr |e investigator |4 oth | |
| 700 | 1 | |a Korkowski, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Koski, Susanna |e investigator |4 oth | |
| 700 | 1 | |a Li, Simon |e investigator |4 oth | |
| 700 | 1 | |a López, José García-Sicilia |e investigator |4 oth | |
| 700 | 1 | |a Majda-Stanisławska, Ewa |e investigator |4 oth | |
| 700 | 1 | |a Maldonado, Yvonne |e investigator |4 oth | |
| 700 | 1 | |a Marshall, Gary |e investigator |4 oth | |
| 700 | 1 | |a Martinón-Torres, Federico |e investigator |4 oth | |
| 700 | 1 | |a Meyer, Jay |e investigator |4 oth | |
| 700 | 1 | |a Mirani, Gayatri |e investigator |4 oth | |
| 700 | 1 | |a Montañà, Josep-Lluís Arimany |e investigator |4 oth | |
| 700 | 1 | |a Muñoz, Flor |e investigator |4 oth | |
| 700 | 1 | |a Nachman, Sharon |e investigator |4 oth | |
| 700 | 1 | |a Martínez, Silvina Natalini |e investigator |4 oth | |
| 700 | 1 | |a Ogbuagu, Onyema |e investigator |4 oth | |
| 700 | 1 | |a Paavola, Pauliina |e investigator |4 oth | |
| 700 | 1 | |a Patel, Nehali |e investigator |4 oth | |
| 700 | 1 | |a Paulsen, Grant |e investigator |4 oth | |
| 700 | 1 | |a Ramchandra, Mahalakshmi |e investigator |4 oth | |
| 700 | 1 | |a Riesenberg, Robert |e investigator |4 oth | |
| 700 | 1 | |a Ruedebusch, Paula |e investigator |4 oth | |
| 700 | 1 | |a Senders, Shelly |e investigator |4 oth | |
| 700 | 1 | |a Seppa, Ilkka |e investigator |4 oth | |
| 700 | 1 | |a Sexter, Joanna |e investigator |4 oth | |
| 700 | 1 | |a Sharp, Stephan |e investigator |4 oth | |
| 700 | 1 | |a Sher, Lawrence |e investigator |4 oth | |
| 700 | 1 | |a Simonsen, Kari |e investigator |4 oth | |
| 700 | 1 | |a Slechta, Stacy |e investigator |4 oth | |
| 700 | 1 | |a Smith, Michael |e investigator |4 oth | |
| 700 | 1 | |a Smith, Yvonne |e investigator |4 oth | |
| 700 | 1 | |a Stryczynska-Kazubska, Joanna |e investigator |4 oth | |
| 700 | 1 | |a Suryadevara, Manika |e investigator |4 oth | |
| 700 | 1 | |a Talaat, Kawsar |e investigator |4 oth | |
| 700 | 1 | |a Ukkonen, Benita |e investigator |4 oth | |
| 700 | 1 | |a Valdivieso, Mariano Miranda |e investigator |4 oth | |
| 700 | 1 | |a Vanchiere, John |e investigator |4 oth | |
| 700 | 1 | |a Walter, Emmanuel |e investigator |4 oth | |
| 700 | 1 | |a Wiedermann, Bernhard |e investigator |4 oth | |
| 700 | 1 | |a Wisman, Paul |c Jr |e investigator |4 oth | |
| 700 | 1 | |a Yudovich, Martin |e investigator |4 oth | |
| 700 | 1 | |a Zerbini, Cristiano |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 388(2023), 7 vom: 16. Feb., Seite 621-634 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:388 |g year:2023 |g number:7 |g day:16 |g month:02 |g pages:621-634 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa2211031 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 388 |j 2023 |e 7 |b 16 |c 02 |h 621-634 | ||